Abstract
These data demonstrate that plasma TGFBl is a independent marker which could be used to monitor the persistence and/or recurrence of disease in lung cancer patients. The end RT TGFDl levels might be used to choose patients who need further adjuvent treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology, Biology, Physics
Paper Title
Journal
Date
